These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
320 related articles for article (PubMed ID: 33986248)
1. A KLF4/PiHL/EZH2/HMGA2 regulatory axis and its function in promoting oxaliplatin-resistance of colorectal cancer. Deng X; Kong F; Li S; Jiang H; Dong L; Xu X; Zhang X; Yuan H; Xu Y; Chu Y; Peng H; Guan M Cell Death Dis; 2021 May; 12(5):485. PubMed ID: 33986248 [TBL] [Abstract][Full Text] [Related]
2. Long noncoding RNA PiHL regulates p53 protein stability through GRWD1/RPL11/MDM2 axis in colorectal cancer. Deng X; Li S; Kong F; Ruan H; Xu X; Zhang X; Wu Z; Zhang L; Xu Y; Yuan H; Peng H; Yang D; Guan M Theranostics; 2020; 10(1):265-280. PubMed ID: 31903119 [TBL] [Abstract][Full Text] [Related]
3. TRIM25 regulates oxaliplatin resistance in colorectal cancer by promoting EZH2 stability. Zhou S; Peng J; Xiao L; Zhou C; Fang Y; Ou Q; Qin J; Liu M; Pan Z; Hou Z Cell Death Dis; 2021 May; 12(5):463. PubMed ID: 33966039 [TBL] [Abstract][Full Text] [Related]
4. Elevating H3K27me3 level sensitizes colorectal cancer to oxaliplatin. Wang Q; Chen X; Jiang Y; Liu S; Liu H; Sun X; Zhang H; Liu Z; Tao Y; Li C; Hu Y; Liu D; Ye D; Liu Y; Wang M; Zhang X J Mol Cell Biol; 2020 Feb; 12(2):125-137. PubMed ID: 31065671 [TBL] [Abstract][Full Text] [Related]
5. LncRNA CACS15 contributes to oxaliplatin resistance in colorectal cancer by positively regulating ABCC1 through sponging miR-145. Gao R; Fang C; Xu J; Tan H; Li P; Ma L Arch Biochem Biophys; 2019 Mar; 663():183-191. PubMed ID: 30639170 [TBL] [Abstract][Full Text] [Related]
6. MALAT1 Is Associated with Poor Response to Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2. Li P; Zhang X; Wang H; Wang L; Liu T; Du L; Yang Y; Wang C Mol Cancer Ther; 2017 Apr; 16(4):739-751. PubMed ID: 28069878 [TBL] [Abstract][Full Text] [Related]
7. The c-Myc/miR-27b-3p/ATG10 regulatory axis regulates chemoresistance in colorectal cancer. Sun W; Li J; Zhou L; Han J; Liu R; Zhang H; Ning T; Gao Z; Liu B; Chen X; Ba Y Theranostics; 2020; 10(5):1981-1996. PubMed ID: 32104496 [TBL] [Abstract][Full Text] [Related]
8. Suppression MGP inhibits tumor proliferation and reverses oxaliplatin resistance in colorectal cancer. Huang C; Wang M; Wang J; Wu D; Gao Y; Huang K; Yao X Biochem Pharmacol; 2021 Jul; 189():114390. PubMed ID: 33359068 [TBL] [Abstract][Full Text] [Related]
9. LncRNA-NEF suppressed oxaliplatin resistance and epithelial-mesenchymal transition in colorectal cancer through epigenetically inactivating MEK/ERK signaling. Shi CJ; Xue ZH; Zeng WQ; Deng LQ; Pang FX; Zhang FW; Fu WM; Zhang JF Cancer Gene Ther; 2023 Jun; 30(6):855-865. PubMed ID: 36782047 [TBL] [Abstract][Full Text] [Related]
10. Downregulation of MEIS1 mediated by ELFN1-AS1/EZH2/DNMT3a axis promotes tumorigenesis and oxaliplatin resistance in colorectal cancer. Li Y; Gan Y; Liu J; Li J; Zhou Z; Tian R; Sun R; Liu J; Xiao Q; Li Y; Lu P; Peng Y; Peng Y; Shu G; Yin G Signal Transduct Target Ther; 2022 Mar; 7(1):87. PubMed ID: 35351858 [TBL] [Abstract][Full Text] [Related]
11. Knockdown of ADAM17 inhibits cell proliferation and increases oxaliplatin sensitivity in HCT-8 colorectal cancer through EGFR-PI3K-AKT activation. Zhang Q; Wang C; Han X; Yang G; Ge Z; Zhang G Biochem Biophys Res Commun; 2018 Sep; 503(4):2333-2339. PubMed ID: 29964008 [TBL] [Abstract][Full Text] [Related]
12. Lnc-RP11-536 K7.3/SOX2/HIF-1α signaling axis regulates oxaliplatin resistance in patient-derived colorectal cancer organoids. Li Q; Sun H; Luo D; Gan L; Mo S; Dai W; Liang L; Yang Y; Xu M; Li J; Zheng P; Li X; Li Y; Wang Z J Exp Clin Cancer Res; 2021 Nov; 40(1):348. PubMed ID: 34740372 [TBL] [Abstract][Full Text] [Related]
13. SNHG4-mediated PTEN destabilization confers oxaliplatin resistance in colorectal cancer cells by inhibiting ferroptosis. Li SQ; Xu WT; Yin YX; Wei HT; Li KZ; Xie MZ; Lv F; Xie LY; Hu BL Apoptosis; 2024 Jun; 29(5-6):835-848. PubMed ID: 38573492 [TBL] [Abstract][Full Text] [Related]
14. Overexpression of MEG3 sensitizes colorectal cancer cells to oxaliplatin through regulation of miR-141/PDCD4 axis. Wang H; Li H; Zhang L; Yang D Biomed Pharmacother; 2018 Oct; 106():1607-1615. PubMed ID: 30119236 [TBL] [Abstract][Full Text] [Related]
15. PRMT5 functionally associates with EZH2 to promote colorectal cancer progression through epigenetically repressing CDKN2B expression. Yang L; Ma DW; Cao YP; Li DZ; Zhou X; Feng JF; Bao J Theranostics; 2021; 11(8):3742-3759. PubMed ID: 33664859 [No Abstract] [Full Text] [Related]
16. MEG3 is a prognostic factor for CRC and promotes chemosensitivity by enhancing oxaliplatin-induced cell apoptosis. Li L; Shang J; Zhang Y; Liu S; Peng Y; Zhou Z; Pan H; Wang X; Chen L; Zhao Q Oncol Rep; 2017 Sep; 38(3):1383-1392. PubMed ID: 28731151 [TBL] [Abstract][Full Text] [Related]
17. Downregulation of AC092894.1 promotes oxaliplatin resistance in colorectal cancer via the USP3/AR/RASGRP3 axis. Zheng Z; Wu M; Li H; Xu W; Yang M; Pan K; Ni Y; Jiang T; Zheng H; Jin X; Zhang Y; Ding L; Fu J BMC Med; 2023 Apr; 21(1):132. PubMed ID: 37013584 [TBL] [Abstract][Full Text] [Related]
18. Long noncoding RNA SNHG14 facilitates colorectal cancer metastasis through targeting EZH2-regulated EPHA7. Di W; Weinan X; Xin L; Zhiwei Y; Xinyue G; Jinxue T; Mingqi L Cell Death Dis; 2019 Jul; 10(7):514. PubMed ID: 31273190 [TBL] [Abstract][Full Text] [Related]
19. Long non-coding RNAs: Key regulators in oxaliplatin resistance of colorectal cancer. Qi FF; Yang Y; Zhang H; Chen H Biomed Pharmacother; 2020 Aug; 128():110329. PubMed ID: 32502843 [TBL] [Abstract][Full Text] [Related]
20. β-hydroxybutyrate resensitizes colorectal cancer cells to oxaliplatin by suppressing H3K79 methylation in vitro and in vivo. Deng M; Yan P; Gong H; Li G; Wang J Mol Med; 2024 Jun; 30(1):95. PubMed ID: 38910244 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]